Krystal Biotech Expands Gene Therapy Platform

Krystal Biotech ( (KRYS) ) has issued an announcement.

On May 9, 2025, Krystal Biotech presented a poster at the Society for Investigative Dermatology Annual Meeting, detailing the expansion of its HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases. The studies demonstrated that the company’s gene therapy vectors, KB111 and KB112, can effectively transduce keratinocytes and express ATPases with minimal toxicity, indicating promising potential for treating these rare skin conditions.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Spark’s Take on KRYS Stock

According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.

Krystal Biotech’s strong financial performance and strategic growth plans, highlighted by revenue growth and European market expansion, are key strengths. However, technical indicators and high valuation present risks. The company’s ability to manage operational challenges and sustain growth will be crucial in influencing future stock performance.

To see Spark’s full report on KRYS stock, click here.

More about Krystal Biotech

Krystal Biotech, Inc. operates in the biotechnology industry, focusing on gene therapy solutions for rare skin diseases. The company is known for its HSV-1-based gene therapy platform, which has been approved for treating dystrophic epidermolysis bullosa and is being expanded to address other conditions like Hailey-Hailey and Darier diseases.

Average Trading Volume: 331,581

Technical Sentiment Signal: Sell

Current Market Cap: $4.03B

See more data about KRYS stock on TipRanks’ Stock Analysis page.